Videos

Binod Dhakal, MD, MS, discusses why patients could benefit from earlier use of chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma.

Bhavana Pothuri, MD, discusses the biggest unmet needs for patients with endometrial cancer.

Aman Chauhan, MD, discusses the mechanism and benefits of lutetium oxodotreotide.

In an interview with Targeted Oncology, Evandro D. Bezerra, MD, discusses brexucabtagene autoleucel for relapsed/refractory B-cell ALL.

Laura Huppert, MD, discusses a real-world study looking at the implications for using sequential ADCs in patients with breast cancer.

Mikkael A. Sekeres MD, MS, discusses the primary differences between imetelstat and other treatments available for patients with low- to intermediate-1 risk myelodysplastic syndromes.

Meredith McKean, MD, discusses a novel mRNA therapy for the treatment of solid tumors.

Nausheen Ahmed, MD, discusses the guidelines for monitoring patients after receiving CAR T-cell therapy.

Regina Barragan-Carrillo, MD, discusses a pilot study evaluating the use of camu camu in combination with ipilimumab and nivolumab for treating metastatic renal cell carcinoma.

Renal cell carcinoma specialists analyze the case of a 59-year-old woman with RCC, focusing on the partial response observed on CT imaging four months after initiating combination therapy with nivolumab and ipilimumab.

Medical experts examine strategies for monitoring treatment response in patients initiating first-line immune checkpoint inhibitor-based therapy for metastatic renal cell carcinoma.

Focusing on the future of CLL/SLL treatment, Mazyar Shadman, MD, MPH, discusses promising therapies in the pipeline.

Matthew Hadfield, DO, discusses what community oncologists should know about immunotherapy toxicities.

Drs Koprivnikar and Chedid highlight prognostic scoring systems in MDS.

Medical experts discuss currently available treatments MDS.

Francis P. Worden, MD, discusses the background of a study evaluating lenvatinib for the treatment of patients with radioiodine-refractory differentiated thyroid cancer, including in those with BRAF-mutated, wild-type and BRAF untested tumors.

Matthew Galsky, MD, discusses the disease-free survival of nivolumab vs placebo in patients with high-risk muscle-invasive bladder cancer.

Timothy F. Cloughesy, MD, director of UCLA’s neuro-oncology program and distinguished professor in neurology, discusses the mechanism of action of vorasidenib.

Ali Duffens, MD, discusses the relative effectiveness of different detection modalities in identifying breast cancer recurrences.